Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Dopheide, JF; Adam, L; Wiedmer, S; Kaspar, M; Silbernagel, G; Baumgartner, I; Drexel, H.
Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease.
Curr Vasc Pharmacol. 2021; 19(6): 634-642. Doi: 10.2174/1570161119666210111123621
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Silbernagel Günther
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Patients with peripheral artery disease (PAD) fall under the category of a very high cardiovascular risk. Although consequent lipid-lowering therapy (LLT) is advised, only sparse data on attained target level in PAD exists. OBJECTIVES: We aimed to analyse contemporary guideline recommendations for LLT in symptomatic PAD patients. METHODS: A monocentric, prospective, observational study involving 200 symptomatic PAD patients was conducted. Guideline target level attainment and LLT were analysed between 2017 and 2019. RESULTS: Overall, 78.5% of the patients were on statin therapy, mainly of high intensity, with atorvastatin in 50% and rosuvastatin in 33% of the cases. The average statin dosage adjusted for simvastatin was 55 mg/d. Low density lipoprotein-cholesterol (LDL-C) was <1.8 mmol/L in 53% and <1.4 mmol/L in 34% of the cases. Mean LDL-C levels were at 1.85 ± 0.88 mmol/L. We observed no difference in the treatment and the target level attainment of patients with a stable PAD (intermittent claudication) or chronic critical PAD. However, patients with ≥ 1 vascular region affected (i.e., coronary and/or cerebrovascular) were treated more intensively and had lower LDL-C levels than patients with PAD alone. CONCLUSION: It appears that there are more awareness and improvement of previously documented undertreatment of LDL-C levels in symptomatic PAD patients. Although statin treatment is initiated in the majority of patients, our findings call for a continuously intensified LLT in symptomatic PAD patients.
Find related publications in this database (Keywords): Peripheral artery disease; lipid-lowering therapy; statins; low-density lipoprotein-cholesterol; target attainment; car-diovascular risk